Biogen Inc.
BIIB
NASDAQ298.66
Biogen Inc.
NASDAQ:BIIB
RECENT
PRICE
298.66
P/E
RATIO
12.71
(PEG:0.13)
P/E RATIO
RELATIVE
TO S&P
0.60
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
- - Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 05/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Fiscal year
5.53
0.64
1.90
- -
10.04
2.02
2.33
- -
14.02
2.68
4.41
- -
15.23
3.38
3.16
- -
18.69
3.98
5.75
- -
20.83
5.09
6.09
- -
23.18
5.80
6.80
- -
29.26
7.86
(4.91)
- -
41.05
12.42
11.23
- -
46.66
15.37
13.32
- -
52.42
16.95
17.38
- -
57.73
11.94
12.17
- -
65.66
21.62
25.87
- -
76.85
31.47
34.25
- -
83.56
24.86
22.86
- -
73.65
10.44
22.43
- -
68.23
20.44
10.90
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.59
21.12
0.90
17.52
0.94
19.86
0.58
21.65
0.69
21.39
1.04
26.51
1.10
29.26
14.81
36.38
1.22
45.73
2.79
40.63
3.33
55.59
9.23
59.33
4.32
63.64
3.58
71.32
3.43
66.50
1.98
73.08
(1.61)
89.86
CAPEX per share
Book Value per share
339
316
292
287
252
242
238
237
236
231
218
213
205
187
161
149
149
Comm.Shares outs.(m)
- -
- -
- -
28.3
1.63
- -
20.7
0.96
- -
14.4
0.20
- -
14.1
0.68
- -
18.2
1.12
- -
23.5
1.58
- -
27.6
1.62
- -
25.5
1.40
- -
22.8
1.14
- -
16.6
0.75
- -
24.5
1.04
- -
14.5
0.58
- -
8.4
0.35
- -
11.7
0.31
- -
27.9
0.93
- -
11.3
0.53
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/12/22 | Q4)
Total liabilities
$10,222 m.
Total assets
$24,554 m.
Long-term debt
$6,614 m.
Cash and equiv.
$3,419 m.
Goodwill $5,749 m.
Retained earnings $16,959 m.
Common stock 144 m. shares
Market Capitalisation
$37,357 m. (as of 28/5/23)
5,049
34.2%
5,516
33.6%
6,932
36.3%
9,703
40.9%
10,764
45.4%
11,449
45.0%
12,274
43.5%
13,453
43.8%
14,378
49.0%
13,445
33.8%
10,982
25.9%
10,173
32.0%
Revenue (m)
Operating margin
359
1,234
366
1,380
532
1,862
688
2,935
600
3,547
683
3,703
1,081
2,539
1,017
4,431
681
5,889
457
4,001
488
1,556
518
3,047
Depreciation (m)
Net profit (m)
26.0%
24.5%
25.4%
25.0%
24.2%
26.9%
25.1%
30.2%
24.4%
33.0%
25.1%
32.3%
47.9%
20.7%
24.2%
32.9%
16.3%
41.0%
19.7%
29.8%
3.0%
14.2%
17.6%
29.9%
Income tax rate
Net profit margin
2,063
1,061
6,425
1,587
687
6,962
1,427
592
8,620
2,453
582
10,809
4,123
6,522
9,373
5,312
6,513
12,140
4,505
5,935
12,613
4,346
5,937
13,040
3,518
4,872
13,343
3,145
7,828
10,700
3,558
6,604
10,896
6,518
6,614
13,398
Working capital (m)
Long-term debt (m)
Equity (m)
15.6%
18.9%
19.2%
16.6%
18.6%
19.8%
18.7%
21.0%
21.6%
24.5%
27.6%
27.2%
21.5%
24.6%
37.8%
20.0%
22.7%
30.5%
13.5%
22.2%
20.1%
20.9%
23.9%
34.0%
27.1%
26.6%
44.1%
20.1%
21.2%
37.4%
9.3%
7.8%
14.3%
14.9%
15.6%
22.7%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
2,610
3,540
4,698
Receivables
2,327
1,962
1,705
Inventory
1,069
1,352
1,344
Other
881
741
1,849
Current assets
6,887
7,857
9,791
Acc. Payable
455
589
492
Debt due
- -
999
- -
Other
3,287
2,710
2,781
Current liab.
3,742
4,298
3,273
100.0%
130.5%
100.0%
12.4%
100.0%
60.8%
100.0%
(34.4)%
100.0%
33.4%
100.0%
162.7%
100.0%
26.4%
100.0%
52.8%
100.0%
82.1%
100.0%
91.6%
100.0%
181.6%
100.0%
53.8%
Plowback ratio
Div.&Repurch. to FCF
Biogen Inc. (US) started trading on September 2, 1991 (cik: 0000875045), operates in the Healthcare sector (Drug Manufacturers—General industry), has 9,610 full-time employees, and is led by Mr. Christopher A. Viehbacher. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
-6.32%
5.42%
Cash flow
-20.55%
-33.11%
Earnings
8.89%
17.94%
Dividends
- -
- -
Book value
1.83%
6.25%
Insider trading
Type
Shares
Date
Singhal Priya
Other
341
03/02/23
Singhal Priya
Exempt
297
03/02/23
Singhal Priya
InKind
144
03/02/23
Singhal Priya
Exempt
297
03/02/23
Singhal Priya
InKind
543
03/02/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
3,534
3,682
3,376
2,853
13,445
2021
2,694
2,775
2,779
2,734
10,982
2022
2,532
2,589
2,509
2,544
10,173
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
8.70
9.58
4.36
2.22
24.86
2021
2.75
3.01
2.21
2.47
10.44
2022
2.04
7.10
7.61
3.69
20.44
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
02/27/2023
Amyloid Gains Converts in Debate Over Alzheimer’s Treatments
The Wall Street Journal - Read more...
01/06/2023
New Alzheimer’s Drug Approved by FDA, Promises to Slow Disease
The Wall Street Journal - Read more...
11/30/2022
New Alzheimer’s Drug Shows Positive Results but Side Effects
The Wall Street Journal - Read more...
11/10/2022
Biogen Names Viehbacher New CEO
The Wall Street Journal - Read more...
10/28/2022
Volunteer Dies Testing Eisai-Biogen Alzheimer’s Drug During Study
The Wall Street Journal - Read more...
10/10/2022
Alzheimer’s Drugs Advance but Slowing Disease Remains a Challenge
The Wall Street Journal - Read more...
09/26/2022
Biogen to Pay $900 Million Over Alleged Physician Kickbacks
The Wall Street Journal - Read more...
05/03/2022
Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment
The Wall Street Journal - Read more...
05/03/2022
Biogen CEO to Resign After Alzheimer’s Drug Struggles
The Wall Street Journal - Read more...
04/07/2022
Medicare Limits Payments for Biogen’s Alzheimer’s Drug
The Wall Street Journal - Read more...
03/14/2022
Biogen and Eisai Rewrite Alzheimer’s Drug Marketing Pact
The Wall Street Journal - Read more...
02/23/2022
Medicare Proposal on Alzheimer’s Drug Draws Criticism From Drugmakers
The Wall Street Journal - Read more...
01/28/2022
Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
The Wall Street Journal - Read more...
01/12/2022
Biogen, PayPal, Block, Ally Financial: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
01/12/2022
Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients
The Wall Street Journal - Read more...
01/04/2022
How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer’s Drug
The Wall Street Journal - Read more...
12/20/2021
Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half
The Wall Street Journal - Read more...
11/09/2021
Biogen Investigates Death of Aduhelm Patient
The Wall Street Journal - Read more...
10/20/2021
Biogen’s New Alzheimer’s Drug Meets Slow Rollout
The Wall Street Journal - Read more...
09/21/2021
Apple iPhone Features Would Detect Depression, Cognitive Decline
The Wall Street Journal - Read more...
09/13/2021
Airbnb, Apache, Biogen: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
08/27/2021
Biogen’s New Alzheimer’s Drug Beyond Reach for Many Patients
The Wall Street Journal - Read more...
08/12/2021
VA Health System Won’t Cover Biogen’s Alzheimer’s Drug
The Wall Street Journal - Read more...
07/22/2021
Biogen Sees Heavy Patient Interest in New Alzheimer’s Drug
The Wall Street Journal - Read more...
07/09/2021
FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer’s Drug
The Wall Street Journal - Read more...
07/09/2021
Biogen Alzheimer’s Drug Will Exceed the $56,000 List Price for Many, Analysis Says
The Wall Street Journal - Read more...
07/08/2021
FDA Narrows Suggested Uses for New Alzheimer’s Drug
The Wall Street Journal - Read more...
06/28/2021
Costly New Alzheimer’s Drug Could Force Medicare to Restrict Access
The Wall Street Journal - Read more...
06/11/2021
FDA’s Approval of Alzheimer’s Drug Leads to Third Adviser’s Resignation
The Wall Street Journal - Read more...
06/10/2021
GameStop, Clover Health, FuelCell Energy: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
06/07/2021
First Alzheimer’s Drug to Slow Disease Is Approved by FDA
The Wall Street Journal - Read more...